ZSAN - Zosano Pharma Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Zosano Pharma Corporation

34790 Ardentech Court
Fremont, CA 94555
United States

Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. John P. WalkerChairman, CEO & Pres39.52kN/A1949
Ms. Georgia L. ErbezChief Bus. Officer, CFO & Principal Accounting Officer251kN/A1967
Dr. Donald J. Kellerman Pharm.D.VP of Clinical Devel. & Medical Affairs387.08kN/A1955
Mr. Eric ScharinVP of Operations and EngineeringN/AN/A1966
Dr. Thorsten von Stein M.D., Ph.D.Chief Medical OfficerN/AN/A1962
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Corporate Governance

Zosano Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.